Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesSales of Property, Plant and EquipmentShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

TriSalus Life Sciences (TLSI) Depreciation & Amortization (CF) (2022 - 2025)

Historic Depreciation & Amortization (CF) for TriSalus Life Sciences (TLSI) over the last 4 years, with Q3 2025 value amounting to $163000.0.

  • TriSalus Life Sciences' Depreciation & Amortization (CF) fell 1043.96% to $163000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $693000.0, marking a year-over-year decrease of 697.99%. This contributed to the annual value of $744000.0 for FY2024, which is 877.19% up from last year.
  • According to the latest figures from Q3 2025, TriSalus Life Sciences' Depreciation & Amortization (CF) is $163000.0, which was down 1043.96% from $165000.0 recorded in Q2 2025.
  • TriSalus Life Sciences' Depreciation & Amortization (CF)'s 5-year high stood at $194000.0 during Q4 2023, with a 5-year trough of -$54000.0 in Q4 2022.
  • Moreover, its 4-year median value for Depreciation & Amortization (CF) was $173500.0 (2024), whereas its average is $156166.7.
  • In the last 5 years, TriSalus Life Sciences' Depreciation & Amortization (CF) surged by 45925.93% in 2023 and then crashed by 1494.85% in 2025.
  • Over the past 4 years, TriSalus Life Sciences' Depreciation & Amortization (CF) (Quarter) stood at -$54000.0 in 2022, then soared by 459.26% to $194000.0 in 2023, then fell by 0.52% to $193000.0 in 2024, then fell by 15.54% to $163000.0 in 2025.
  • Its last three reported values are $163000.0 in Q3 2025, $165000.0 for Q2 2025, and $172000.0 during Q1 2025.